Results 151 to 160 of about 17,845 (225)

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

High levels of elevated blood pressure among pregnant and postpartum women with HIV, regardless of dolutegravir initiation. [PDF]

Clin Infect Dis
Bengtson A.
europepmc   +1 more source

HIV-1 genetic diversity and reverse transcriptase resistance mutations in Benin before dolutegravir era, West Africa. [PDF]

PLoS One
Tchiakpe E, Keke RK, Recordon-Pinson P, Diouara AAM, Andreola ML, Bachabi M, Afangnihoun A, Gbaguidi E, Osawe S, Issiaka Maiga A, Diop-Ndiaye H, Touré-Kane C, Yessoufou A.   +12 more
europepmc   +1 more source

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. [PDF]

Open Forum Infect Dis
Mujuru HA, White E, Kekitiinwa AR, Lugemwa A, Kityo C, Violari A, Ahimbisibwe GM, Variava E, Archary M, Cotton M, Ounchanum P, Puthanakit T, Kanjanavanit S, Ngampiyaskul C, Kobbe R, Bandi S, Epalza C, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Kaudha E, Cressey TR, Giaquinto C, Jafta L, Bamford A, Rojo P, Gibb DM, Turkova A, Ford D.   +28 more
europepmc   +1 more source

Brain Structure of South African Children Born to Mothers on Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy. [PDF]

J Pediatric Infect Dis Soc
Bradford LE, Wedderburn CJ, Malaba TR, Theunissen H, Ringshaw JE, Bourke NJ, Williams SCR, He N, Read L, Waitt C, Reynolds H, Colbers A, Read J, Davel L, Orrell C, Taegtmeyer M, Wang D, Khoo S, Myer L, Donald KA.   +19 more
europepmc   +1 more source

A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens. [PDF]

J Antimicrob Chemother
Dickinson L, Else L, Venter WDF, Boffito M, Brand R, Waitt C, Hill A, Khoo S.   +7 more
europepmc   +1 more source

A cross-sectional study of viral load suppression among youth living with HIV in Namibia. [PDF]

South Afr J HIV Med
Kamangu JWN, Mboweni SH.
europepmc   +1 more source

Virological outcomes of dolutegravir-based versus other antiretroviral regimens in people living with HIV: A systematic review and meta-analysis. [PDF]

BMC Infect Dis
Weldemhret L, Dejene TA, Gebrehiwot GT, Legese H, Wasihun AG, Weldemariam AG.   +5 more
europepmc   +1 more source

HIV low-level viraemia: considerations for prevention and treatment in an era of highly effective and durable antiretroviral therapy regimens. [PDF]

J Int AIDS Soc
Vojnov L, Bekker LG, Cohen MS, Jahn A, Havlir D, Boeras D, Ford N, Kumarasamy N, Broyles LN.   +8 more
europepmc   +1 more source

Brief Report: Dolutegravir-Based Therapy, Diet, Physical Activity, and Weight Gain: A 48-week Prospective Cohort in South Africa. [PDF]

J Acquir Immune Defic Syndr
Tien D, Chandiwana N, Shazi G, Chen G, Mabweazara S, Moosa MS, Gupta RK, Pillay D, Marconi VC, Hedt-Gauthier B, Venter WDF, Siedner MJ, McCluskey SM, Manne-Goehler J.   +13 more
europepmc   +1 more source